Analysis of Cancer Risks in Populations near Nuclear Facilities

The U.S. Nuclear Regulatory Commission (U.S.NRC) requested that the National Research Council provide an assessment of cancer risks in populations near U.S.NRC-licensed nuclear facilities. This assessment is being carried out in two consecutive phases. The first phase (Phase 1) was completed in May 2012 and resulted in a consensus report. The second phase (Phase 2) would be the assessment of cancer risks informed by the recommendations of the Phase 1 report.


The Phase 1 report identified two scientifically sound approaches for carrying out the assessment of cancer risks in populations near U.S. nuclear facilities. The Phase 1 report also recommended a pilot study involving seven nuclear facilities to assess the feasibility of the recommended approaches. The U.S.NRC announced in October 2012 that it was asking the National Research Council to undertake the recommended pilot study.


History of Phase 1 Committee Meetings


October 20, 2011, Washington, DC

Click links to view this meeting's agenda, webcast, and presentations.

 

July 21, 2011, Irvine, CA

Click links to view this meeting's agenda and presentations.

 

May 23, 2011, Atlanta, GA

Click links to view this meeting's agenda, webcast and presentations.


April 18, 2011, Burr Ridge, IL

Click links to view this meeting's agenda, webcast, and presentations. 

 

February 24, 2011, Washington, DC

Click links to view this meeting's agenda, webcast, and presentations.


General Information About the Phase 1 Study:


USNRC Study Request (Press Announcement)

Study Background

Study Task

Committee Bios

 

Information on National Academy of Sciences Studies:

Study Process


This page contains the most current information on this study. Please check back for updates.

 

If you would like to be added on the Cancer Risk Study Listserv and receive notifications about the next study phase, please send us an email at crs@nas.edu with the title ADD ME TO THE LIST. For more information or to submit questions or comments, please email us.